Tim Smith

This interview with Dr. Arkin involved a discussion, in honor of June being National Scleroderma Awareness Month, of information on underlying causes and new research on the skin condition.

New data indicating this connection suggests a need for clinicians to take into account cardiovascular examination for patients with both the skin disorder and symptoms suggestive of incident venous thromboembolism.

This research was conducted to identify distinct subgroups of those with atopic dermatitis, and the findings may help to promote better counseling and treatment options.

These findings are relevant given that if labels are incorrectly identified, those with allergies may be at risk of severe reactions or receive suboptimal treatment.

Recent research from Japan indicates that there are several comorbidities identified for patients with psoriasis, raising awareness of incidental findings in CT analysis.

New data indicates that psoriasis patients who are naïve to biological therapies may benefit from early intervention with secukinumab, though further research is needed.

This research from Japan on the shifting preferences for individuals with psoriasis in the pre and post-pandemic era may indicate the effects of such events on treatment options.

This study highlighted the strong effects of environmental factors on eczema, especially given the higher prevalence of the skin condition in industrialized countries.

New research has led to the development of an algorithm designed to help improve detection of allergic reactions to antibiotics, given that antibiotics are among the most common medication adverse event causes.

Research into global prevalence rates of autoimmune conditions such as multiple sclerosis and psoriasis highlights important information for future research and medical resource allocation.

These findings suggest that disparities in reporting data may be present in nursing homes, with implications for surveillance of nursing homes, priority setting for facilities, as well as payment and research.

New data indicates that increased risk for offspring in developing different disorders is associated with maternal alopecia areata exposure, expanding the available information on alopecia and maternal autoimmunity.

This study examined survival of brodalumab after switching from ixekizumab, providing more information on real-world, non-medical switching for patients with psoriasis.

New data indicates the usefulness of spironolactone as an alternative to oral antibiotics for women in the UK with acne vulgaris, given increasing resistance to antibiotics due to widespread use.

New data from a systematic review of randomized control trials indicated that moderate-to-severe psoriasis patients benefited from deucravacitinib as a first line treatment.

In this interview, Marinkovich discussed the implications of the FDA’s landmark approval of B-VEC topical gene therapy for patients with the “butterfly disease.”

During this interview segment, Stucky continued on his team's findings on a newspaper article’s association with increased prescribing rates of oral minoxidil, explaining the study’s limitations and implications.

In this interview, Stucky discussed his team’s research into an uptick in oral minoxidil prescribing rates for hair loss that had immediately followed the publication of a New York Times article.

Friedman spoke in this interview segment on improvements that have been made and improvements that he believes are needed to affect change regarding atopic dermatitis treatment disparities.

During this interview segment, Friedman further explored the topics in his presentation on fixing disparities in care for eczema patients through teledermatology.

The long-awaited FDA approval follows data that demonstrated about 70% wound closure by 6 months in dystrophic epidermolysis bullosa patients treated with B-VEC.

In this interview, Friedman described his conference presentation on treating atopic dermatitis through telemedicine to address the disparities in care that are visible around the world.

In this interview, Hebert discussed recent positive topline results from the ADORING 1 trial on tapinarof cream for atopic dermatitis patients aged 2 years and older.

New data on trends among 22 million UK citizens examined the burden and rising prevalence of autoimmune diseases, as well as environmental factors and co-occurence of other conditions.

A new research letter highlighted findings that show a lack of viral reactivation in hepatitis patients with psoriasis, as well as other strong results, opening the door for new studies to confirm these findings.

A review of randomized clinical trials using the World Health Organization’s framework for clinical adherence to point to key knowledge gaps in self-exam knowledge among those at high risk for skin cancer.

The Food and Drug Administration approved the intradermal microdroplet injection, a hydrating gel product designed to smooth out patients’ skin in those over 21 of all Fitzpatrick skin types.

This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.

It was announced by ARS Pharmaceuticals, Inc., that a US Food and Drug Administration Drug Advisory Committee voted in favor of a new intranasal epinephrine treatment for severe allergic reactions.

New phase 3 data on patients with eczema in China and Japan showed that crisaborole, 2%, was efficacious and safe in patients aged 2 and older, lining up with data from studies done in Western countries.